Pramlintide

Main evidence: Human clinical trials. Updated 2026-10-28.

What research and users report, not a recommendation or medical advice. Many of these products are not approved for human use. Ask your doctor. Packs report what sources say, each with its evidence label. A claim labelled community, educator, manufacturer or animal has not been validated in humans.

Summary

This information-only pack summarizes human trials, a historical United States label, safety findings and the result of an Australian ARTG search for pramlintide.

Safety and cautions

Safety statements are source-specific and should not be generalized across products, formulations or routes.

Australian legal status

No Australian ARTG listing for pramlintide or Symlin was located in the public search performed on 2026-10-28. The clinical evidence and dose examples below come from overseas trials and United States labeling, not Australian authorization. Any access to an unapproved therapeutic good is subject to applicable TGA pathways and circumstances.

What the sources say

In a separate 52-week randomized study of 656 insulin-treated people with type 2 diabetes, the 120 microgram twice-daily pramlintide arm had a 0.62 percentage-point HbA1c reduction and mean weight change of -1.4 kg at week 52, compared with +0.7 kg with placebo; transient nausea was the most common adverse event. The trial was conducted outside Australia and included selected participants. (Human clinical trials; Hollander PA et al., randomized pramlintide study in type 2 diabetes, PubMed record (issue March 2003; accessed 2026-10-28)., 2026-10-28)
In a 52-week double-blind randomized study of 480 people with type 1 diabetes using insulin, add-on pramlintide produced a mean HbA1c reduction of 0.67% at week 13 versus 0.16% with placebo; the report described weight loss rather than weight gain. Nausea and anorexia were common early adverse effects. This is trial evidence, not proof of benefit for other populations or non-standard products. (Human clinical trials; Whitehouse F et al., randomized pramlintide study in type 1 diabetes, Diabetes Care (published 2002-04-01)., 2002-04-01)
The FDA-approved Symlin label describes pramlintide as an amylin analogue used alongside mealtime insulin in selected people with type 1 or type 2 diabetes whose glucose control remains inadequate; it slows gastric emptying and suppresses post-meal glucagon. This is United States labeling and is not an Australian approval or indication. (Manufacturer information; FDA, SYMLIN (pramlintide acetate) prescribing information (revised 06/2014; accessed 2026-10-28)., 2026-10-28)
Historical United States label context only: the FDA label describes subcutaneous administration before major meals, starting at 15 micrograms for type 1 diabetes and increasing in 15-microgram steps to a label maximum of 30 or 60 micrograms; for type 2 diabetes it describes starting at 60 micrograms and increasing to 120 micrograms. It specifies at least 3 days between titrations and an initial 50% reduction in mealtime insulin with frequent glucose monitoring. These figures are not Australian prescribing guidance; no Australian pramlintide product was located in the ARTG search. The cited US product is a pen presentation, not a BAC-water reconstitution protocol. (Manufacturer information; FDA, SYMLIN (pramlintide acetate) prescribing information (revised 06/2014; accessed 2026-10-28)., 2026-10-28)
The FDA label carries a boxed warning for severe hypoglycaemia when pramlintide is used with insulin, especially in type 1 diabetes. It lists hypoglycaemia unawareness and confirmed gastroparesis as contraindications, and reports nausea, vomiting, anorexia and headache among common adverse reactions. It also says not to mix pramlintide and insulin in the same injection. These are foreign-label safety findings, not Australian product directions. (Manufacturer information; FDA, SYMLIN (pramlintide acetate) prescribing information (revised 06/2014; accessed 2026-10-28)., 2026-10-28)
The TGA ARTG keyword search for pramlintide returned no matching results when checked on 2026-10-28. This is a dated database search result, not a formal TGA ruling and not proof that no exceptional access pathway could apply. (Educator material (not peer reviewed); TGA ARTG keyword results for pramlintide (no matching results; checked 2026-10-28)., 2026-10-28)
The TGA states that prescription medicines must be entered on the ARTG as registered medicines; it also describes defined pathways for access to some unapproved goods. The existence of a pathway does not make a product generally TGA-approved or establish eligibility in an individual case. (Educator material (not peer reviewed); TGA, Prescription medicines; checked 2026-10-28., 2026-10-28)
The TGA says unapproved therapeutic goods may be accessed only through certain defined pathways; that general statement does not establish access eligibility for pramlintide. (Educator material (not peer reviewed); TGA, Unapproved therapeutic goods; checked 2026-10-28., 2026-10-28)
The separate TGA ARTG keyword search for Symlin also returned no matching results when checked on 2026-10-28. (Educator material (not peer reviewed); TGA ARTG keyword results for Symlin (no matching results; checked 2026-10-28)., 2026-10-28)

Sources

Dosing, stacking and protocol details are not published here.